Clinical Trial Update: Investigation of the Role of FHL-1 and Myostatin in Intensive Care Unit Acquired Paresis (ICUAP) [NA]

View source ↗

Summary

A clinical trial investigating the role of FHL-1 and Myostatin in Intensive Care Unit-acquired weakness and muscle wasting has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intensive Care Unit Acquired Weakness
• Muscle Wasting

Snippet

Sponsor: Imperial College London | Conditions: Intensive Care Unit Acquired Paresis, Muscle Wasting | NA | Status: COMPLETED